RxDoctor Payments Data

Mark Obrien, MD

Internal Medicine · Benton Harbor, MINPI 1841221348

Payments from drug & device makers

$200in general payments, 2019–2025

Across 12 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$29
  • Lilly USA, LLC$26
  • Merck$25
  • Global Blood Therapeutics, Inc.$23
  • Shire North American Group Inc$18
  • Supernus Pharmaceuticals, Inc.$18
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$200 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$1,984
Medicare patients
93
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$67,883
JardianceEmpagliflozin36$40,513
FarxigaDapagliflozin Propanediol30$31,143
TrulicityDulaglutide30$28,409
JanuviaSitagliptin Phosphate29$26,378
OzempicSemaglutide22$21,288
Atrovent HfaIpratropium Bromide36$18,756
Advair HfaFluticasone Propion/Salmeterol50$17,210
XareltoRivaroxaban22$15,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,369
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$9,800
Breo ElliptaFluticasone/Vilanterol13$9,305
Albuterol Sulfate HfaAlbuterol Sulfate253$6,891
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$6,031
SymbicortBudesonide/Formoterol Fumarate23$5,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$40,51336 claims
AstraZenecaFarxiga, Symbicort$15$37,13653 claims
Lilly USA, LLCTrulicity$26$28,40930 claims
MerckJanuvia$25$26,37829 claims
Novo NordiskOzempic, Levemir$29$23,22436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Benton Harbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →